Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Updated Oct 3, 2026
AI dilution summary: the dominant contractual driver and its mechanism, then each further driver ranked, for Signal8 Pro subscribers.
